Abstracts tagged "Randomized Trial"

Abstract Number: 1211 • ACR Convergence 2020
Relationship Between Changes in Lipid Levels and Improvement in Disease Activity Outcomes in Patients with Rheumatoid Arthritis Receiving Upadacitinib Treatment: Pooled Analysis of Data from Two Phase 3 Studies
Christina Charles-Schoeman¹, Jon Giles², Nancy Lane³, Ernest Choy⁴, Heidi Camp⁵, Yanna Song⁶, Samuel Anyanwu⁵ and Iain McInnes⁷, ¹University of California, Los Angeles, Los Angeles, CA, ²Columbia University, New York, NY, ³University of California, Davis, Sacramento, CA, ⁴CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom, ⁵AbbVie Inc., North Chicago, IL, ⁶AbbVie Inc., North Chicago,, IL, ⁷Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Upadacitinib (UPA) is an oral Janus kinase (JAK) inhibitor engineered to have greater selectivity for JAK1 vs JAK2, JAK3, and tyrosine kinase 2, and…
Abstract Number: 2009 • ACR Convergence 2020
Treat-to Target for Early RA Patients in Usual Clinical Practice, a Randomized Study with a Favorable Effect of a Second Oral Pulse of Prednisolone. the Amsterdam COBRA Treat-to-target Study
Linda Hartman¹, Linda Rasch², Samina Turk³, Marieke ter Wee¹, Pit Kerstens⁴, Conny van der Laken⁵, Mike Nurmohamed⁶, Dirkjan van Schaardenburg⁷, Lilian van Tuyl⁸, Alexandre Voskuyl¹, Maarten Boers⁷ and Willem Lems¹, ¹Amsterdam Rheumatology and Immunology Center, location Amsterdam UMC, VUmc, Amsterdam, Netherlands, ²Amsterdam Rheumatology and Immunology Center, location Amsterdam UMC, VUmc, Amsterdam, ³Amsterdam Rheumatology and Immunology Center, location Reade, Amsterdam, Netherlands, ⁴Westfriesgasthuis, Hoorn, Netherlands, ⁵Amsterdam Rheumatology and immunology Center, location Amsterdam UMC, VU medical center, Amsterdam, Netherlands, ⁶Amsterdam Rheumatology and immunology Center, location Reade and Amsterdam UMC, VU medical center, Amsterdam, Netherlands, ⁷Amsterdam Rheumatology and immunology Center | Reade and Amsterdam UMC, Amsterdam, Netherlands, ⁸Nivel, Utrecht, Netherlands
Background/Purpose: EULAR guidelines advise to start with methotrexate (MTX) for early rheumatoid arthritis (RA), either alone or combined with prednisolone. Since this strategy is not…
Abstract Number: 0799 • ACR Convergence 2020
Effectiveness of Electronic Drug Monitoring Feedback in Order to Increase Adherence in RA Patients Starting with a Biological DMARD
Renske Hebing¹, Wouter Bos¹, Mike Nurmohamed² and Bart van den Bemt³, ¹Amsterdam Rheumatology and Immunology Center | Reade, Amsterdam, Netherlands, ²Amsterdam Rheumatology and immunology Center, location Reade and Amsterdam UMC, VU medical center, Amsterdam, Netherlands, ³Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: Medication non-adherence in rheumatoid arthritis (RA) is associated with disease flares, increased disability and increased costs. Electronic Monitoring Feedback (EMF) to improve adherence has…
Abstract Number: 1213 • ACR Convergence 2020
Discrepancy Between the Multi-biomarker Disease Activity Score and Clinical Disease Activity Scores in a 2‑Part, Multicenter Study of Repository Corticotropin Injection (Acthar® Gel) for Patients with Persistently Active Rheumatoid Arthritis
Roy Fleischmann¹, Jingyu Liu², Julie Zhu², Oscar Segurado³ and Daniel Furst*⁴, ¹Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX, ²Mallinckrodt Pharmaceuticals, Bedminster, NJ, ³SSI Strategy, San Jose, CA, ⁴Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA, Los Angeles, CA
Background/Purpose: Assessment of disease activity in RA with validated measures, such as the Disease Activity Score with 28 joint count and erythrocyte sedimentation rate (DAS28-ESR)…
Abstract Number: 2010 • ACR Convergence 2020
Stable versus Tapered and Withdrawn Treatment with Tumor Necrosis Factor Inhibitor in Rheumatoid Arthritis Remission: A Randomized, Open-Label, Phase 4, Non-Inferiority Trial
Siri Lillegraven¹, Nina Paulshus Sundlisæter¹, Anna-Birgitte Aga¹, Joseph Sexton¹, Inge C. Olsen², Åse Lexberg³, Tor Magne Madland⁴, Hallvard Fremstad⁵, Christian Høili⁶, Gunnstein Bakland⁷, Cristina Spada⁸, Hilde Haukeland⁹, Inger Myrnes Hansen¹⁰, Ellen Moholt¹, Till Uhlig¹, Daniel H. Solomon¹¹, Désirée van der Heijde¹², Tore K. Kvien¹ and Espen A. Haavardsholm¹, ¹Diakonhjemmet Hospital, Oslo, Norway, ²Oslo University Hospital, Oslo, Norway, ³Vestre Viken HF, Drammen, Norway, ⁴Haukeland University Hospital, Bergen, Norway, ⁵Ålesund Hospital, Ålesund, Norway, ⁶Hospital Øsftfold HF, Moss, Norway, ⁷University Hospital of North Norway, Tromsø, Norway, ⁸Revmatismesykehuset, Lillehammeer, Norway, ⁹Martina Hansens Hospital, Bærum, Norway, ¹⁰Helgelandssykehuset Mo i Rana, Mo i Rana, Norway, ¹¹Brigham & Women's Hospital and Harvard Medical School, Boston, MA, ¹²Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Remission is the preferred treatment target in rheumatoid arthritis (RA), and many patients require biologic disease-modifying antirheumatic drugs (DMARDs) to reach this state. It…
Abstract Number: 0865 • ACR Convergence 2020
Efficacy and Safety of Evobrutinib (M2951) in Adult Patients with Systemic Lupus Erythematosus Who Received Standard of Care Therapy: A Phase II, Randomized, Double-blind, Placebo-controlled Dose Ranging Study
Daniel J Wallace¹, Thomas Dörner², David Pisetsky³, F Jorge Sanchez-Guerrero⁴, Amy Kao⁵, Dana Parsons-Rich⁵, Anand Patel⁶, Yulia Zima⁵, Claire Le Bolay⁷, Karthinathan Thangavelu⁶ and Maria Dall'Era⁸, ¹Cedars-Sinai Medical Center, Beverly Hills, CA, ²DRFZ and Charité University Hospitals, Berlin, Germany, ³Duke University Medical Center, Durham, NC, ⁴University Health Network/Sinai Health system, Toronto, ON, Canada, ⁵EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ⁶EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, ⁷Merck KGaA, Darmstadt, Germany, ⁸Division of Rheumatology, University of California, San Francisco, CA
Background/Purpose: Bruton’s tyrosine kinase (BTK) is involved in signalling pathways known to be important to the pathogenesis of systemic lupus erythematosus (SLE). Evobrutinib is a…
Abstract Number: 1344 • ACR Convergence 2020
Guselkumab, an IL-23 Inhibitor That Specifically Binds to the IL23p19-Subunit, for Active Psoriatic Arthritis: One Year Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Patients Who Were Biologic-Naïve or TNFα Inhibitor-Experienced
Christopher Ritchlin¹, Philip Helliwell², Wolf-Henning Boehncke³, Elizabeth Hsia⁴, Alexa Kollmeier⁵, Ramanand Subramanian⁶, Xie Xu⁷, Shihong Sheng⁶, Yusang Jiang⁶, Bei Zhou⁶ and Atul Deodhar⁸, ¹Department of Medicine, University of Rochester Medical Center, Rochester, NY, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Geneva University Hospitals, Geneva, Switzerland, ⁴Janssen Research & Development, LLC and University of Pennsylvania Medical Center, Spring House, PA, ⁵Janssen Research & Development, LLC, La Jolla, CA, ⁶Janssen Research & Development, LLC, Spring House, PA, ⁷Janssen Research & Development, LLC, San Marcos, CA, ⁸Oregon Health & Science University, Portland, OR
Background/Purpose: Guselkumab (GUS), a monoclonal antibody that specifically binds to the p19-subunit of IL-23, is approved to treat psoriasis (PsO). At Week 24 of the…
Abstract Number: 2012 • ACR Convergence 2020
A Phase IIb, Randomized, Double-blind Study in Patients with Rheumatoid Arthritis Evaluating the Safety and Efficacy of Evobrutinib Compared with Placebo in Patients with an Inadequate Response to Methotrexate
Charles Peterfy¹, Maya Buch², Ernest Choy³, Georg Schett⁴, Dana Parsons-Rich⁵, Anand Patel⁶, Yulia Zima⁵, Claire Le Bolay⁷ and Mark Genovese⁸, ¹Spire Sciences, Inc., Boca Raton, FL, ²Centre of Musculoskeletal Research, School of Biological Sciences, University of Manchester, Manchester, United Kingdom, ³CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom, ⁴Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany, ⁵EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ⁶EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, ⁷Merck KGaA, Darmstadt, Germany, ⁸Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: Bruton’s tyrosine kinase (BTK) is involved in multiple signalling pathways potentially implicated in rheumatoid arthritis (RA). Evobrutinib is a highly selective, oral BTK inhibitor.…
Abstract Number: 0875 • ACR Convergence 2020
Secukinumab Provides Sustained Improvements in Subgroup Analyses of Joint Tenderness and Swelling in Patients with Psoriatic Arthritis: 5‑Year Results from the Phase 3 FUTURE 2 Study
Iain McInnes¹, Hector Chinoy², Darren Asquith³, Abigail White³ and Corine Gaillez⁴, ¹Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²The University of Manchester, Manchester, United Kingdom, ³Novartis Pharmaceuticals UK Ltd., London, United Kingdom, ⁴Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab, a fully human monoclonal antibody that neutralizes interleukin‑17A, has shown long-term efficacy and tolerability in patients with psoriatic arthritis (PsA) in FUTURE 2.…
Abstract Number: 1348 • ACR Convergence 2020
What Influence Do Clinical Domains Other Than Arthritis Have on Composite Clinical Outcomes in Psoriatic Arthritis?: Comparison of Treatment Effects in the SEAM-PsA Trial
Philip Helliwell¹, Philip Mease², Arthur Kavanaugh³, Laura Coates⁴, Alexis Ogdie⁵, Atul Deodhar⁶, Vibeke Strand⁷, Ervant Maksabedian⁸, Gregory Kricorian⁹, Lyrica Liu⁹, David Collier¹⁰ and Dafna Gladman¹¹, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ³UC San Diego Health System, San Diego, CA, ⁴University of Oxford, Oxford, United Kingdom, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Oregon Health & Science University, Portland, OR, ⁷Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ⁸Amgen Inc., LOS ANGELES, CA, ⁹Amgen Inc., Thousand Oaks, CA, ¹⁰Amgen, Thousand Oaks, CA, ¹¹Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis is broadly characterized by clinical domains such as enthesitis, dactylitis, nail manifestations, and psoriasis. How these clinical domains influence the response to…
Abstract Number: 2023 • ACR Convergence 2020
Efficacy and Safety of Upadacitinib in Patients with Active Ankylosing Spondylitis: 1-Year Results from a Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Extension
Atul Deodhar¹, Désirée van der Heijde², Joachim Sieper³, Filip Van den Bosch⁴, Walter Maksymowych⁵, Tae-Hwan Kim⁶, Mitsumasa Kishimoto⁷, Andrew Östör⁸, Bernard Combe⁹, Yunxia Sui¹⁰, Xin Wang¹⁰, Alvina D. Chu¹¹ and In-Ho Song¹⁰, ¹Oregon Health & Science University, Portland, OR, ²Leiden University Medical Center, Leiden, Netherlands, ³Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴Ghent University Hospital, Ghent, Belgium, ⁵University of Alberta, Edmonton, AB, Canada, ⁶Hanyang University Hospital for Rheumatic Diseases, Seoul, Seoul-t'ukpyolsi, Republic of Korea, ⁷Department Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, ⁸Cabrini Medical Center, Monash University, Malvern, Victoria, Australia, ⁹University of Montpellier, Montpellier, France, ¹⁰AbbVie Inc., North Chicago, IL, ¹¹AbbVie, North Chicago, IL
Background/Purpose: Upadacitinib (UPA), a Janus kinase (JAK) inhibitor, was efficacious and well tolerated vs placebo (PBO) during the first 14 weeks (wks) of the phase…
Abstract Number: 0886 • ACR Convergence 2020
Achievement of Partial Remission and Inactive Disease in Upadacitinib-Treated Patients with Ankylosing Spondylitis
Atul Deodhar¹, Andrew Östör², Anna Maniccia³, Fabiana Ganz⁴, Tianming Gao³, Alvina D. Chu⁵ and Denis Poddubnyy⁶, ¹Oregon Health & Science University, Portland, OR, ²Cabrini Medical Center, Monash University, Malvern, Victoria, Australia, ³AbbVie Inc., North Chicago, IL, ⁴AbbVie Inc., Baar, Switzerland, ⁵AbbVie, North Chicago, IL, ⁶Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Assessment of SpondyloArthritis international Society (ASAS) response criteria and AS Disease Activity Score (ASDAS) are both commonly used, rigorous composite indices consisting of components…
Abstract Number: 1372 • ACR Convergence 2020
Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis and Axial Involvement
Atul Deodhar¹, Roberto Ranza², Fabiana Ganz³, Tianming Gao⁴, Jaclyn K Anderson⁴ and Andrew Östör⁵, ¹Oregon Health & Science University, Portland, OR, ²Hospital de Clinicas, Universidade Federal de Uberlândia, Uberlândia, Brazil, ³AbbVie Inc., Baar, Switzerland, ⁴AbbVie Inc., North Chicago, IL, ⁵Cabrini Medical Center, Monash University, Malvern, Victoria, Australia
Background/Purpose: Upadacitinib (UPA) has demonstrated efficacy for the treatment of AS in patients (pts) who were NSAID inadequate responders (IR).1 Pts with psoriatic arthritis (PsA)…
Abstract Number: 2024 • ACR Convergence 2020
Effects of Filgotinib on Spinal Lesions in Patients with Ankylosing Spondylitis: Magnetic Resonance Imaging Data from the Placebo-Controlled, Double‑Blind, Randomized TORTUGA Trial
Walter Maksymowych¹, Mikkel Østergaard², Robert Landewé³, William Barchuk⁴, Ke Liu⁴, Chantal Tasset⁵, Leen Gilles⁵, Thijs Hendrikx⁶, Robin Besuyen⁶ and Xenofon Baraliakos⁷, ¹University of Alberta, Edmonton, AB, Canada, ²Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, ³Amsterdam University Medical Center & Zuyderland Hospital, Amsterdam, Netherlands, ⁴Gilead Sciences, Inc., Foster City, CA, ⁵Galapagos NV, Mechelen, Belgium, ⁶Galapagos BV, Leiden, Netherlands, ⁷Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany
Background/Purpose: The oral, selective Janus kinase 1 inhibitor filgotinib (FIL) significantly improved Spondyloarthritis Research Consortium of Canada (SPARCC) MRI inflammation scores (bone marrow edema) in…
Abstract Number: 0896 • ACR Convergence 2020
Impact of Upadacitinib on Reducing Pain in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Trials in Patients with Inadequate Response to Non-biologic or Biologic DMARDs
Iain McInnes¹, William Tillett², Philip Mease³, Kurt de Vlam⁴, Louis Bessette⁵, Ralph Lippe⁶, Anna Maniccia⁷, Patrick Zueger⁷, Dai Feng⁷, Koji Kato⁸ and Andrew Östör⁹, ¹Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Royal National Hospital for Rheumatic Diseases, Bath, UK; Department of Pharmacy and Pharmacology, University of Bath, Bath, UK, Bath, United Kingdom, ³Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ⁴Department of Rheumatology, University of Leuven, Belgium, Leuven, Belgium, ⁵Laval University, Quebec, Canada, ⁶AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁷AbbVie Inc., North Chicago, IL, ⁸AbbVie Inc, North Chicago, IL, ⁹Cabrini Medical Center, Monash University, Malvern, Victoria, Australia
Background/Purpose: Pain is a dominant symptom of psoriatic arthritis (PsA), and pain reduction is a priority for patients (pts) that is often assessed in clinical…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].